Patents by Inventor Patrick Chaltin

Patrick Chaltin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260070896
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Application
    Filed: January 27, 2025
    Publication date: March 12, 2026
    Inventors: Sara ALLASIA, Philippe ARZEL, Patrick CHALTIN, Amuri KILONDA, Arnaud MARCHAND, Jean-Christophe VANHERCK, Thomas VOETS, Joris VRIENS, Melanie REICH, André WELBERS
  • Publication number: 20250346569
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 13, 2025
    Inventors: Arnaud MARCHAND, Jean-Christophe VANHERCK, Patrick CHALTIN, Melanie REICH, Sebastian KRÜGER, Amuri KILONDA, Thomas VOETS, Joris VRIENS
  • Publication number: 20250346605
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 13, 2025
    Inventors: Arnaud MARCHAND, Jean-Christophe VANHERCK, Patrick CHALTIN, Melanie REICH, Sebastian KRÜGER, Damien MARCHAND, Thomas VOETS, Joris VRIENS
  • Patent number: 12404266
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: September 2, 2025
    Assignee: Katholieke Universiteit Leuven
    Inventors: Sara Allasia, Philippe Arzel, Patrick Chaltin, Amuri Kilonda, Arnaud Marchand, Jean-Christophe Vanherck, Thomas Voets, Joris Vriens, Melanie Reich, André Welbers
  • Patent number: 12209081
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Grant
    Filed: May 12, 2024
    Date of Patent: January 28, 2025
    Assignee: Katholieke Universiteit Leuven
    Inventors: Patrick Chaltin, Arnaud Marchand, Jean-Christophe Vanherck, Thomas Voets, Joris Vriens, Melanie Reich, André Welbers
  • Publication number: 20240336602
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Application
    Filed: May 12, 2024
    Publication date: October 10, 2024
    Inventors: Sara ALLASIA, Philippe ARZEL, Patrick CHALTIN, Amuri KILONDA, Arnaud MARCHAND, Jean-Christophe VANHERCK, Thomas VOETS, Joris VRIENS, Melanie REICH, André WELBERS
  • Patent number: 11939324
    Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: March 26, 2024
    Assignees: reMYND N.V., Katholieke Universiteit Leuven
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom Francois L. Van Dooren, Arnaud Didier Marie Marchand, Amuri Kilonda, Sara Allasia, Patrick Chaltin
  • Publication number: 20240051949
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Application
    Filed: November 24, 2021
    Publication date: February 15, 2024
    Inventors: Sara ALLASIA, Philippe ARZEL, Patrick CHALTIN, Amuri KILONDA, Arnaud MARCHAND, Thomas VANHERCK, Thomas VOETS, Joris VRIENS, Melanie REICH, André WELBERS
  • Publication number: 20230391739
    Abstract: The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 7, 2023
    Inventors: Sara ALLASIA, Philippe ARZEL, Patrick CHALTIN, Amuri KILONDA, Arnaud MARCHAND, Thomas VANHERCK, Thomas VOETS, Joris VRIENS, Melanie REICH, André WELBERS
  • Publication number: 20230099111
    Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom Francois L. Van Dooren, Arnaud Didier Marie Marchand, Amuri Kilonda, Sara Allasia, Patrick Chaltin
  • Patent number: 11548881
    Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 10, 2023
    Assignees: reMYND N.V., Katholieke Universiteit Leuven
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom Francois L. Van Dooren, Arnaud Didier Marie Marchand, Amuri Kilonda, Sara Allasia, Patrick Chaltin
  • Publication number: 20200095238
    Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
    Type: Application
    Filed: May 11, 2018
    Publication date: March 26, 2020
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom Francois L. Van Dooren, Arnaud Didier Marie Marchand, Amuri Kilonda, Sara Allasia, Patrick Chaltin
  • Publication number: 20190054068
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    Type: Application
    Filed: September 19, 2018
    Publication date: February 21, 2019
    Inventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas de la Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
  • Patent number: 10117850
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 6, 2018
    Assignees: Katholieke Universiteit Leuven, K.U.Leuven R&D, reMYND
    Inventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas de la Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
  • Patent number: 9499563
    Abstract: The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: November 22, 2016
    Assignee: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Patrick Chaltin, Frauke Christ, Zeger Debyser, Marc De Maeyer, Arnaud Marchand, Damien Marchand, Arnout Voet
  • Publication number: 20160324828
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Applicants: Katholieke Universiteit Leuven, K.U.Leuven R&D, reMYND
    Inventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas de la Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
  • Patent number: 9434722
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: September 6, 2016
    Assignees: Katholieke Universiteit Leuven, K.U. Leuven R&D, reMYND
    Inventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas De La Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
  • Patent number: 9284271
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 15, 2016
    Assignees: Katholieke Universiteit Leuven, K.U. Leuven R&D, reMYND
    Inventors: Gerard Griffioen, Tom Van Dooren, Verónica Rojas De La Parra, Arnaud Marchand, Sara Alassia, Amuri Kilonda, Patrick Chaltin
  • Patent number: 9266832
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: February 23, 2016
    Assignees: Katholieke Universiteit Levun, K. U. Leuven R&D reMYND
    Inventors: Gerard Griffioen, Tom Van Dooren, Verónica Rojas De La Parra, Sara Allasia, Arnaud Marchand, Amuri Kilonda, Patrick Chaltin
  • Publication number: 20150336965
    Abstract: The present invention relates to compounds of formula (A), as further defined herein, having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. The invention further relates to the use of such compounds, optionally combined with one or more other drugs having antiviral activity, for the treatment of animals suffering from viral infections, in particular HIV infection.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Inventors: Patrick Chaltin, Frauke Christ, Zeger Debyser, Marc De Maeyer, Arnaud Marchand, Damien Marchand, Arnout Voet